Navigation Links
ORTHOCON® Names David J. Hart Vice President of Business Operations
Date:3/15/2012

IRVINGTON, N.Y., March 15, 2012 /PRNewswire/ -- ORTHOCON®, Inc., a privately-held surgical device company, today announced that David J. Hart has been appointed Vice President of Business Operations. Mr. Hart will be responsible for in-licensing and acquiring new products and technologies for development and distribution by ORTHOCON's R&D and commercial teams. 

Mr. Hart joins ORTHOCON from Alpine Capital Group, a leading family office investment fund where, as President and Chief Investment Officer, he was responsible for all private equity and indirect capital investments and healthcare research. Prior to Alpine Capital, David was Principal and Senior Research Analyst at Apelles Investment Management, a cross-capital healthcare investment fund focused on public and private investing in medical device, healthcare service, and healthcare information technology companies. Mr. Hart began his career in the merger and acquisition groups at Thomas Weisel and Partners and Duff and Phelps. He earned a MBA from Columbia University and a BA from Duke where he was a member of the varsity golf team.

"I am thrilled to have David on our senior leadership team," said John J. Pacifico, President and Chief Executive Officer of ORTHOCON. "Having known David for several years and watched him achieve tremendous professional success directly relevant to ORTHOCON's business plan, I know he is perfect for this role and I fully expect him to add significant value to ORTHOCON and to our shareholders."

"I've had the opportunity to watch ORTHOCON evolve over the last five years. John has built a dynamic organization with a robust R&D pipeline and a truly differentiated commercialization strategy," said David Hart. "I am excited to join the ORTHOCON team and look forward to helping John execute on his strategic vision for the company."

About ORTHOCON
Founded in 2005, ORTHOCON develops, acquires, manufactures, and markets surgical products. In 2011, ORTHOCON announced the commercial introduction of its first FDA cleared product, Hemasorb Resorbable Hemostatic Bone Putty, and the clearance of Hemasorb Apply, a proprietary applicator designed to deliver Hemasorb and other ORTHOCON products presently under development. Also in 2011, ORTHOCON announced a strategic partnership with Bezwada Biomedical which gave ORTHOCON worldwide rights to develop and market Bezwada's absorbable polyurethane technology for bone applications. 

ORTHOCON is funded by leading international venture capital investment firms. The company occupies 8,000 square feet at its state-of-the-art facility in Irvington, New York. For more information, please visit www.orthocon.com.


'/>"/>
SOURCE ORTHOCON, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ORTHOCON®, Inc. Receives 510(k) Clearance to Market HEMASORB Apply™
2. ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB®
3. ORTHOCON® Announces U.S. Market Launch of HEMASORB®
4. Zeus Healthcare Names Larry Havelis as CEO
5. RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation
6. InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development
7. SalesCongo Names Ken Kaisen CEO
8. UNT System Names Jacobson Founding Dean of College of Pharmacy
9. LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors
10. Premier Research Names Etienne Drouet Executive Director, Oncology Europe
11. Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled ... wearable activity and sleep monitoring solutions for the global scientific community. The company’s ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
Breaking Medicine News(10 mins):